1. Home
  2. ZBAI vs BEAT Comparison

ZBAI vs BEAT Comparison

Compare ZBAI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZBAI

ATIF Holdings Limited Ordinary Shares

N/A

Current Price

$6.50

Market Cap

68.1M

ML Signal

N/A

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

N/A

Current Price

$1.48

Market Cap

58.6M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ZBAI
BEAT
Founded
2015
2015
Country
United States
United States
Employees
6
16
Industry
Professional Services
Retail: Computer Software & Peripheral Equipment
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
68.1M
58.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZBAI
BEAT
Price
$6.50
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.75
AVG Volume (30 Days)
2.6K
473.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.54
52 Week High
$11.94
$4.00

Technical Indicators

Market Signals
Indicator
ZBAI
BEAT
Relative Strength Index (RSI) 48.84 46.38
Support Level $5.68 $1.33
Resistance Level $7.44 $1.82
Average True Range (ATR) 0.45 0.11
MACD 0.03 0.02
Stochastic Oscillator 47.19 29.74

Price Performance

Historical Comparison
ZBAI
BEAT

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: